Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 2.54
BIOC's Cash to Debt is ranked lower than
52% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.06 vs. BIOC: 2.54 )
Ranked among companies with meaningful Cash to Debt only.
BIOC' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 2.65 Max: No Debt
Current: 2.54
Equity to Asset 0.49
BIOC's Equity to Asset is ranked lower than
67% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. BIOC: 0.49 )
Ranked among companies with meaningful Equity to Asset only.
BIOC' s Equity to Asset Range Over the Past 10 Years
Min: -18.63  Med: 0.34 Max: 0.83
Current: 0.49
-18.63
0.83
F-Score: 4
Z-Score: -15.54
M-Score: 2.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -3340.17
BIOC's Operating margin (%) is ranked lower than
94% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.66 vs. BIOC: -3340.17 )
Ranked among companies with meaningful Operating margin (%) only.
BIOC' s Operating margin (%) Range Over the Past 10 Years
Min: -1227100  Med: -10033.68 Max: -5928.36
Current: -3340.17
-1227100
-5928.36
Net-margin (%) -3464.53
BIOC's Net-margin (%) is ranked lower than
94% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.98 vs. BIOC: -3464.53 )
Ranked among companies with meaningful Net-margin (%) only.
BIOC' s Net-margin (%) Range Over the Past 10 Years
Min: -1362900  Med: -11588.52 Max: -6890.3
Current: -3464.53
-1362900
-6890.3
ROE (%) -233.73
BIOC's ROE (%) is ranked lower than
96% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.39 vs. BIOC: -233.73 )
Ranked among companies with meaningful ROE (%) only.
BIOC' s ROE (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -233.73
ROA (%) -116.02
BIOC's ROA (%) is ranked lower than
93% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.60 vs. BIOC: -116.02 )
Ranked among companies with meaningful ROA (%) only.
BIOC' s ROA (%) Range Over the Past 10 Years
Min: -694.81  Med: -659.50 Max: -400.76
Current: -116.02
-694.81
-400.76
ROC (Joel Greenblatt) (%) -2177.16
BIOC's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 194 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.03 vs. BIOC: -2177.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BIOC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -3222.72  Med: -2717.73 Max: -1614.63
Current: -2177.16
-3222.72
-1614.63
» BIOC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with BIOC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.91
BIOC's P/B is ranked lower than
73% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.57 vs. BIOC: 3.91 )
Ranked among companies with meaningful P/B only.
BIOC' s P/B Range Over the Past 10 Years
Min: 2.1  Med: 3.76 Max: 7.24
Current: 3.91
2.1
7.24
P/S 39.80
BIOC's P/S is ranked lower than
99.99% of the 243 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.20 vs. BIOC: 39.80 )
Ranked among companies with meaningful P/S only.
BIOC' s P/S Range Over the Past 10 Years
Min: 8.02  Med: 47.00 Max: 110
Current: 39.8
8.02
110
Current Ratio 3.93
BIOC's Current Ratio is ranked higher than
66% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. BIOC: 3.93 )
Ranked among companies with meaningful Current Ratio only.
BIOC' s Current Ratio Range Over the Past 10 Years
Min: 0.02  Med: 4.13 Max: 10.2
Current: 3.93
0.02
10.2
Quick Ratio 3.85
BIOC's Quick Ratio is ranked higher than
70% of the 191 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. BIOC: 3.85 )
Ranked among companies with meaningful Quick Ratio only.
BIOC' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 3.99 Max: 10.09
Current: 3.85
0.02
10.09
Days Inventory 22.36
BIOC's Days Inventory is ranked higher than
81% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.26 vs. BIOC: 22.36 )
Ranked among companies with meaningful Days Inventory only.
BIOC' s Days Inventory Range Over the Past 10 Years
Min: 9.26  Med: 12.06 Max: 23.71
Current: 22.36
9.26
23.71
Days Sales Outstanding 31.20
BIOC's Days Sales Outstanding is ranked higher than
90% of the 155 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.71 vs. BIOC: 31.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 24.51  Med: 46.91 Max: 1825
Current: 31.2
24.51
1825
Days Payable 77.30
BIOC's Days Payable is ranked higher than
66% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.88 vs. BIOC: 77.30 )
Ranked among companies with meaningful Days Payable only.
BIOC' s Days Payable Range Over the Past 10 Years
Min: 107.77  Med: 331.44 Max: 22179.12
Current: 77.3
107.77
22179.12

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.14
BIOC's Price/Net Cash is ranked higher than
62% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.09 vs. BIOC: 5.14 )
Ranked among companies with meaningful Price/Net Cash only.
BIOC' s Price/Net Cash Range Over the Past 10 Years
Min: 2.99  Med: 4.64 Max: 8.21
Current: 5.14
2.99
8.21
Price/Net Current Asset Value 4.50
BIOC's Price/Net Current Asset Value is ranked higher than
65% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.70 vs. BIOC: 4.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
BIOC' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.77  Med: 4.00 Max: 7.19
Current: 4.5
2.77
7.19
Price/Tangible Book 3.89
BIOC's Price/Tangible Book is ranked higher than
58% of the 217 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.71 vs. BIOC: 3.89 )
Ranked among companies with meaningful Price/Tangible Book only.
BIOC' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.64  Med: 3.69 Max: 6.22
Current: 3.89
2.64
6.22
Price/Median PS Value 0.77
BIOC's Price/Median PS Value is ranked higher than
66% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.95 vs. BIOC: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
BIOC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.28  Med: 1.21 Max: 1.8
Current: 0.77
0.28
1.8
Earnings Yield (Greenblatt) (%) -80.74
BIOC's Earnings Yield (Greenblatt) (%) is ranked lower than
91% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.10 vs. BIOC: -80.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BIOC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -560.3  Med: 0.00 Max: 0
Current: -80.74
-560.3
0

More Statistics

Revenue(Mil) $0
EPS $ -1.70
Short Percentage of Float13.82%
52-Week Range $1.09 - 4.91
Shares Outstanding(Mil)18.81

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 1 3
EPS($) -1.08 -0.91
EPS without NRI($) -1.08 -0.91

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare: » details
Traded in other countries:B00.Germany,
» More Articles for BIOC

Headlines

Articles On GuruFocus.com
Biocept (BIOC) Soars on Liquid Biopsy Appreciation, Rigel Pharmaceuticals (RIGL) Mega-deal with Bris Feb 23 2015 

More From Other Websites
Biocept to Present at Upcoming Investment Conferences Feb 02 2016
Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference Jan 25 2016
Biocept CEO Michael W. Nall to Present at the Personalized Medicine World Conference Jan 25 2016
Why Are Investors Driving Up The Price of These 5 Stocks? Jan 12 2016
Biocept (BIOC) Stock Popping on Blue Cross Blue Shield Partnership Jan 12 2016
Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois Jan 12 2016
Biocept Announces In-Network Agreement with Blue Cross Blue Shield of Illinois Jan 12 2016
Here’s Why These Stocks Are In the Green Today Jan 07 2016
Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer Jan 07 2016
Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer Jan 07 2016
Biocept Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund Dec 22 2015
Biocept Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund Dec 22 2015
BIOCEPT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of... Dec 22 2015
Biocept, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 14 2015
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA... Dec 14 2015
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA... Dec 14 2015
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA... Dec 14 2015
BIOCEPT INC Financials Dec 08 2015
Biocept Announces Collaboration with Baylor College of Medicine to Develop Liquid Biopsy Tests for... Dec 07 2015
Biocept Announces Collaboration with Baylor College of Medicine to Develop Liquid Biopsy Tests for... Dec 07 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK